MedTrace Logo

Lansoprazole Intravenous 30 mg Specified Drug-use Survey [Hemostatic Effect/Rebleeding Rate]

NCT02151786 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1120

Last updated 2016-02-23

Study results available
· View outcomes & findings →

Summary

The purpose of this survey is to evaluate the safety (i.e., frequency of adverse events) and efficacy (i.e., hemostatic effect, rate of rebleeding after confirmation of hemostasis) of administration of lansoprazole intravenous 30 milligram (mg) (Takepron Intravenous 30 mg) to a large number of patients in daily medical practice.

Conditions

  • Gastric Ulcer, Duodenal Ulcer, Acute Stress Gastritis, and Acute Gastric Mucosal Lesions

Interventions

DRUG

Lansoprazole

Lansoprazole intravenous 30 mg

Sponsors & Collaborators

Principal Investigators

  • Postmarketing Group Manager · Takeda

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2010-03-31
Completion
2010-03-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02151786 on ClinicalTrials.gov